Diligence memo · auto-generated · as of July 2, 2026
Sernova Corp.
Sernova Corp. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Sernova Corp. operates in Biotechnology, based in LONDON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Sernova Corp. has raised $573K in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $473K on 2024-09-03.
Most recent recorded round closed around 2024-09-03.
Valuation (modeled)modeled
Provath models Sernova Corp. at approximately $2.0M (range $252K–$6.3M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.61× the median modeled value of Pre-Seed Biotechnology companies in 2022–2024 (185 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 60 months.
Last raise 22 mo ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
The last round stepped up 4.7× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 12% of Biotechnology peers (4293 compared).
Modeled value ranks above 5% of those peers.
Closest niche peers: TissueMill Technologies LLC, Aldebaran Therapeutics, Inc., BullFrog AI Holdings, Inc., Vesicle Therapeutics Inc., TAUC3 Biologics Ltd.
Peoplefiled
12 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.